Navigation Links
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
Date:3/26/2008

Forms One of the Largest Sales Teams Promoting a 5-ASA Medicine

BASINGSTOKE, England and PHILADELPHIA, March 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today a co-promotion agreement with TAP Pharmaceutical Products Inc. for LIALDA(TM) (mesalamine) with MMX(R) technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC). This three year agreement is for the U.S. only and will add more than 500 additional sales representatives from TAP to increase the reach and frequency of the Shire sales force, which consists of 120 representatives who are currently detailing LIALDA primarily to gastroenterologists.

"Aligning with TAP, one of the most successful and well-respected GI sales organizations in the industry, is a tremendous benefit for Shire as it will quadruple the Lialda sales force across the United States," said Mike Yasick, senior vice president of Shire's Gastrointestinal Business Unit. "With the added expertise of the TAP team, we'll be able to reach more GI specialists as well as primary care providers with messages about Lialda. Shire's GI team has made Lialda the fastest growing brand of mesalamine and with this collaboration we will bolster the frequency of sales calls to our existing base of specialist physicians."

LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Mesalamines are a part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA), a well-established drug of choice and often a first-line treatment for patients with mild to moderate ulcerative colitis.

"Building on the successful introduction of Lialda, which Shire launched in the first quarter of last year, we are excited to work with the Shire team as together
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportlin...t is available in its catalogue: ,, Brazil Bio..., http://www.reportlinker.com/p0165503/Brazil-Bi...l ,, Brazil Bioethanol Market Analysis and For...ovides detailed analysis and forecasts of the glob...
(Date:11/24/2009)... The New York investment bank KTA Ca...) has agreed an AU$6.7 mil convertible note privat...e private placement was arranged by KTA Capital as..., New York (PRWEB) Novembe...bank KTA Capital, LLC ("KTA Capital") ha...
(Date:11/24/2009)... Health care employment grew by 29...ly one to show consistent growth during the U.S. r... remain in trouble, and health systems are coming ..., instead of just administrators. , ...e employment continued growing in October despite ...
(Date:11/24/2009)... SEATTLE, Nov. 24 Blue Marble Ener...Odessa Public Development Authority (OPDA) were re...mmunity Economic Revitalization Board (CERB) in a ...s first specialty biochemical biorefinery in Linco...ficantly speed the development of our biorefinery ...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
..., , , for routine amplification of up ...7 679 250 units (1 unit/l) , , Cat....at. No. 1 146 165 100 units (5 units/l) , C...at. No. 1 418 432 4 x 250 units (5 units/l) , ..., Cat. No. 1 435 094 20 x 250 units (5 units...
..., , , Explore New Horizons in Amplifica...bine High Yield, Accuracy, and the Prevention , ... , , , Roche Applied Science, which pi...polymerases with the Expand High Fidelity and Expa...ces the Expand High FidelityPLUS PCR , Syst...
... , , , , , , Mark Churchil...el Hempstead, UK, , , , , , ... , , , The data presented here can be...ntum mass spectrometer, , , , , ... , Guidelines on Bioanalytical Method Validat...
Other Biology Technology:Taq DNA Polymerase 2Taq DNA Polymerase 3Expand High FidelityPLUS PCR System 2Expand High FidelityPLUS PCR System 3Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 2Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 3Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 4Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 5Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 6
(Date:11/25/2009)...s and ambulance workers faced a terrifying rescue ...tled to save people from the collapsing Twin Tower...ated as many people as they could in an area which...their jobs even harder was the problem of poor com...s jammed mobile networks with calls and the emerge...
(Date:11/25/2009)...inchpin of the environment, where atmosphere, bios...udents see soil as "just dirt" a place to grow pl... challenged with the task of helping students and ...il in the environment. , A collaborative projec...iversity of Nebraska-Lincoln, Oregon State Univers...
(Date:11/25/2009)...s recently received funding from the National Scie...al to understanding the environment. The three gra...istant professor in the Department of Biological S...e research projects. , His first project, titled...ctions from the Leaf to the Landscape," will exami...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3It's not just dirt! 2Kent State University professors focus research on the environment with grants totaling $890,000 2Misonix Announces the Purchase of Patents From ProRhythm Inc 48765 1Misonix Announces the Purchase of Patents From ProRhythm Inc 48765 2Misonix Announces the Purchase of Patents From ProRhythm Inc 48765 3Autism Family Foundation Introduces The Robert J Keegan Family Center for Autism 48764 1Autism Family Foundation Introduces The Robert J Keegan Family Center for Autism 48764 2Autism Family Foundation Introduces The Robert J Keegan Family Center for Autism 48764 3Early treatment of systemic onset JIA with anakinra restores the IL 18 response 48762 1Early treatment of systemic onset JIA with anakinra restores the IL 18 response 48762 2
...m, The Netherlands, May 26, 2009 There are severa...disease and vascular dementia. Based on an increas...ith Vitamin D deficiency, an article in the curren...ay 2009) by William B. Grant, PhD of the Sunlight,...ggests that further investigation of possible dire...
...d Congress of the European College of Neuropsych...ember 2009 in Istanbul, Turkey. , More than 6,50...sts, neurologists, psychologists and neuroscience ...e ECNP Congress, which is the largest annual high ...nd neuropsychopharmacology in Europe. Renowned exp...
... study published in Disease Models & Mechanisms ,... the influence of known cancer genes on the develo...orm of human skin cancer with limited treatment op...hat direct the cell on whether to divide, migrate ...les that relay these signals become mutated so tha...
Other Biology News:Is vitamin D deficiency linked to Alzheimer's disease and vascular dementia? 2Zebrafish provide a model for cancerous melanoma in humans 2
MYCOPLASMA REMOVAL AGENT from AbD Serotec
Dynabeads Epithelial Enrich from Dynal Biotech
Bovine Albumin from Bovine Serum, Tetramethylrhodamine conjugated/tagged from Molecular Probes (Invitrogen)
PatternHunter from Bioinformatics Solutions Inc.
Biology Products: